Nanoliposomal Delivery of MicroRNA-203 Suppresses Migration of Triple-Negative Breast Cancer through Distinct Target Suppression.
EMT
breast cancer
microRNA
microRNA-203
nanoliposome
nanoparticle
Journal
Non-coding RNA
ISSN: 2311-553X
Titre abrégé: Noncoding RNA
Pays: Switzerland
ID NLM: 101652294
Informations de publication
Date de publication:
27 Jul 2021
27 Jul 2021
Historique:
received:
11
05
2021
revised:
14
07
2021
accepted:
21
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Triple-negative breast cancers affect thousands of women in the United States and disproportionately drive mortality from breast cancer. MicroRNAs are small, non-coding RNAs that negatively regulate gene expression post-transcriptionally by inhibiting target mRNA translation or by promoting mRNA degradation. We have identified that miRNA-203, silenced by epithelial-mesenchymal transition (EMT), is a tumor suppressor and can promote differentiation of breast cancer stem cells. In this study, we tested the ability of liposomal delivery of miR-203 to reverse aspects of breast cancer pathogenesis using breast cancer and EMT cell lines. We show that translationally relevant methods for increasing miR-203 abundance within a target tissue affects cellular properties associated with cancer progression. While stable miR-203 expression suppresses LASP1 and survivin, nanoliposomal delivery suppresses BMI1, indicating that suppression of distinct mRNA target profiles can lead to loss of cancer cell migration.
Identifiants
pubmed: 34449670
pii: ncrna7030045
doi: 10.3390/ncrna7030045
pmc: PMC8395754
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Cell Mol Med. 2011 Dec;15(12):2760-7
pubmed: 21323860
J Oncol. 2015;2015:865816
pubmed: 25883654
PLoS One. 2014 Aug 20;9(8):e105570
pubmed: 25140799
Adv Drug Deliv Rev. 2015 Jan;81:142-60
pubmed: 25450259
PLoS One. 2015 Sep 18;10(9):e0132225
pubmed: 26382657
EMBO Rep. 2008 Jun;9(6):582-9
pubmed: 18483486
Gynecol Oncol. 2014 May;133(2):340-5
pubmed: 24530564
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Oncogene. 2019 Apr;38(16):3061-3076
pubmed: 30617305
Oncogene. 2016 Nov 17;35(46):5977-5988
pubmed: 27292262
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Nature. 2006 May 25;441(7092):537-41
pubmed: 16724069
Clin Cancer Res. 2011 Aug 15;17(16):5287-98
pubmed: 21159887
Nat Rev Drug Discov. 2010 Oct;9(10):775-89
pubmed: 20885409
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11494-11499
pubmed: 29073077
Cancer Res. 2013 Apr 15;73(8):2412-7
pubmed: 23423979
Int J Nanomedicine. 2012;7:49-60
pubmed: 22275822
Mol Cell. 2001 Jun;7(6):1267-78
pubmed: 11430829
Silence. 2012 Jan 09;3(1):1
pubmed: 22230293
NPJ Breast Cancer. 2016 Nov 16;2:16036
pubmed: 28721389
Mol Cell Biol. 2008 Aug;28(15):4772-81
pubmed: 18519590
Cancer J. 2012 May-Jun;18(3):275-84
pubmed: 22647365
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Dev Cell. 2019 May 6;49(3):361-374
pubmed: 31063755
PLoS One. 2015 Jul 01;10(7):e0131350
pubmed: 26132195
Int J Nanomedicine. 2020 Mar 19;15:1903-1914
pubmed: 32256067
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Mol Carcinog. 2017 Feb;56(2):464-477
pubmed: 27253631
Trends Pharmacol Sci. 2009 Nov;30(11):592-9
pubmed: 19837467
Cancer Res. 2014 Nov 1;74(21):6330-40
pubmed: 25164016
Genes Cancer. 2011 Jul;2(7):720-7
pubmed: 22207897
Onco Targets Ther. 2016 Oct 11;9:6203-6210
pubmed: 27785068
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Nat Cell Biol. 2010 Oct;12(10):982-92
pubmed: 20818389
Cancer Res. 2008 Oct 1;68(19):7846-54
pubmed: 18829540
BMC Cancer. 2014 Oct 28;14:785
pubmed: 25348805
Sci Rep. 2013;3:2687
pubmed: 24045437
Nat Commun. 2018 Nov 7;9(1):4671
pubmed: 30405106
J Biol Chem. 2014 Jan 3;289(1):529-39
pubmed: 24247238
Nat Cell Biol. 2017 May;19(5):518-529
pubmed: 28414315
Annu Rev Pathol. 2009;4:199-227
pubmed: 18817506
Nat Cell Biol. 2009 Dec;11(12):1487-95
pubmed: 19935649
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Oncol Res. 2018 Sep 14;26(8):1155-1165
pubmed: 28893347
Cell Cycle. 2012 Apr 1;11(7):1291-5
pubmed: 22421148
Cancer Lett. 2011 May 1;304(1):52-9
pubmed: 21354697
PLoS One. 2018 Feb 2;13(2):e0190245
pubmed: 29394261
Genes Cancer. 2011 Aug;2(8):782-91
pubmed: 22393463
Mol Oncol. 2014 Feb;8(1):83-92
pubmed: 24145123
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Cell Rep. 2014 Oct 9;9(1):104-117
pubmed: 25284788
Int J Nanomedicine. 2019 Jul 11;14:5159-5173
pubmed: 31371954
Nanomedicine. 2013 Jan;9(1):1-14
pubmed: 22684017
Nat Rev Genet. 2008 Feb;9(2):102-14
pubmed: 18197166
Oncotarget. 2015 Apr 20;6(11):8914-28
pubmed: 25871397
IUBMB Life. 2018 Mar;70(3):224-236
pubmed: 29389061
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 28096261
J Exp Clin Cancer Res. 2012 Jun 19;31:58
pubmed: 22713668
Oncol Lett. 2015 Jun;9(6):2639-2646
pubmed: 26137120
Cancer Cell. 2008 Jun;13(6):496-506
pubmed: 18538733
Cell Rep. 2019 Nov 5;29(6):1458-1468.e3
pubmed: 31693888
Nature. 2007 Jun 28;447(7148):1130-4
pubmed: 17554337
EMBO Rep. 2010 Sep;11(9):670-7
pubmed: 20706219
Cancer Discov. 2013 Nov;3(11):1302-15
pubmed: 24002999
Oncotarget. 2014 Jun 30;5(12):4144-4153
pubmed: 24980827
EMBO Mol Med. 2015 Apr 14;7(6):831-47
pubmed: 25872941
Mol Cancer Ther. 2011 Aug;10(8):1470-80
pubmed: 21622730
Genes Dev. 2003 May 15;17(10):1253-70
pubmed: 12756227
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Nat Cell Biol. 2019 Jan;21(1):102-112
pubmed: 30602760
Int Immunol. 2012 May;24(5):293-301
pubmed: 22336533
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Biosci Bioeng. 2015 Oct;120(4):351-8
pubmed: 25910964
Cancer Res. 2010 Jul 15;70(14):5923-30
pubmed: 20570894